ABSTRACT
INTRODUCTION

Pediatric systemic lupus erythematosus (pSLE) with class IV/V lupus nephritis (LN) often requires treatment with corticosteroids (CS)
and other agents such as azathioprine (AZA), methotrexate (MTX), mycophenolate mofetil (MMF), or cyclophosphamide (CYC) [1, 2] .
Although the 5-year survival rate exceeds 95%, the disease may remain intractable in some children [3] and new treatment modalities must sometimes be explored.
Abatacept (ABA) is a recombinant fusion protein that acts by competing with CD28 for binding to CD80/CD86, and inhibits its engagement on T cells and plasma cells [4] . Because both T and B cells play an active role in SLE, it was postulated that ABA could be beneficial in SLE. Several studies in murine models of SLE have shown improvement in both SLE and nephritis activity either with CTLA-4Ig alone or in combination with CYC [5, 6] . Although recent controlled trials of ABA, with and without combination treatment with MMF for adult SLE, did not meet their primary or secondary endpoints, exploratory analyses suggested efficacy in some subgroups [7, 8] .
ABA is currently FDA approved for treatment of juvenile idiopathic arthritis (JIA) and rheumatoid arthritis, however, its use in pSLE has not been reported [9] . This small case series examines ABA in conjunction with MMF as a potentially effective treatment for pSLE in a subset of children who have failed other medications.
MATERIALS AND METHODS
We performed a retrospective analysis of children with pSLE, with class IV and V LN (Table 1) .
Mean SLEDAI scores at time of diagnosis (baseline) and after 12 and 24 weeks of each therapy are shown in Table 2 . Baseline SLEDAI scores were significantly elevated with the lowest score being 19 (Fig. 1) . Mean dose of steroids, levels of dsDNA, C3 level and UPC are also listed in Repeated measures ANOVA for patients with data at all three time points revealed significant decreases in SLEDAI scores for five patients after taking CYC (P = 0.0013) and for four patients after taking ABA ? MMF (P\0.0001). Post hoc pairwise comparisons to baseline at 12 and 24 weeks were significant for both drugs (P = 0.02 and P = 0.006, respectively, for CYC; P = 0.002 and P = 0.0006, respectively, for ABA ? MMF). Since only three patients had SLEDAI scores after 24 weeks on MMF, repeated measures ANOVA was not used for this drug; however, five patients showed some decrease in scores after 12 weeks on MMF (paired t test P = 0.0520).
DISCUSSION
The use of ABA with MMF resulted in improvement in complement (Fig. 4) , dsDNA levels ( Fig. 5 ) and blood counts (CBC) in all five patients despite the previous failure with CYC and MMF monotherapy. Furthermore, it permitted the reduction in the CS dose. UPC improved with all three therapeutic interventions ( Fig. 6 ) which is consistent with previous studies evaluating the use of CYC and MMF in lupus nephritis [12] . When comparing 
